Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 3Astrocytoma 3Oligodendroglioma 2Glioma 2Optic Nerve Glioma 1Head and Neck Neoplasms 1Gliosarcoma 1Ependymoma 1Carcinoma, Squamous Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 28Radiosurgery 19Radiotherapy 17Bevacizumab 12Magnetic Resonance Spectroscopy 9Radiation 6Erlotinib Hydrochloride 6Carboplatin 6Topotecan 5Nivolumab 5Mental Status and Dementia Tests 5Irinotecan 5Capecitabine 5pembrolizumab 4dabrafenib 4Trastuzumab 4Sunitinib 4Pemetrexed 4Ipilimumab 4Filgrastim 4Cyclophosphamide 4Aminolevulinic Acid 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4cabozantinib 3Vorinostat 3TPI-287 3Specimen Handling 3Radiotherapy, Intensity-Modulated 3Methylphenidate 3Lomustine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Brain Neoplasms × Dynamic Contrast Enhanced Magnetic Resonance Imaging × Clear all
NCT01996527 2017-04-17

3T MRI Biomarkers of Glioma Treatment Response

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Terminated
7 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡